VCYT
$33.48
Veracyte, Inc.
Intraday
Recent News
Veracyte (VCYT) Valuation Check After Strong 2025 Earnings And Reaffirmed 2026 Growth Outlook
Veracyte (VCYT) just delivered fourth quarter and full year 2025 results that combined higher revenue with much stronger profitability, while also reaffirming its 2026 guidance for double digit growth tied to its cancer testing portfolio. See our latest analysis for Veracyte. Even with the strong 2025 earnings and reaffirmed 2026 outlook, Veracyte’s recent share price performance has been weak in the short term, with a 30 day share price return of 5.44% and a 90 day share price return of...
Veracyte Q4 Earnings Beat Estimates, Revenues Grow Y/Y, Stock Rises
VCYT posts a 47% y/y Q4 earnings jump and 18.5% revenue growth, beats estimates, lifts margins and sees shares rise after hours.
Veracyte, Inc. Q4 2025 Earnings Call Summary
Moby summary of Veracyte, Inc.'s Q4 2025 earnings call
Veracyte Q4 Earnings Call Highlights
Veracyte (NASDAQ:VCYT) management said fourth-quarter results capped “another outstanding year” of execution, highlighted by double-digit revenue growth, expanding profitability and progress toward multiple new product launches planned for 2026. Fourth-quarter and full-year performance Chief Execut
Veracyte Inc (VCYT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
Veracyte Inc (VCYT) reports robust financial performance with a 19% revenue increase and prepares for significant product launches in 2026.